https://www.selleckchem.com/products/acbi1.html
5%), tildrakizumab (1.0%), and guselkumab (1.5%). In the long-term NMA, risankizumab had the lowest rates of all 3 outcomes (67.5%, 4.4%, and 1.0%, respectively) and the most favorable benefit-risk profile. The results may not be generalizable to real-world populations. Anti-interleukin 23 agents were associated with low rates of safety events. Risankizumab had the most favorable benefit-risk profile in the long term. Anti-interleukin 23 agents were associated with low rates of safety events. Risankizumab had the most favorable benefit-ri
Like
Comment
Share
